BioPharmSignal logoBioPharmSignal

Company Profile

SOLIGENIX Stock Price, News & Catalysts

Ticker:
SNGX
Exchange:
NASDAQ
Sector:
Biopharma
Location:
United States

Stock performance

0.37 USD (-1.36%)

Close

Last updated: September 18, 2026

11.1M USD

Market cap

Why the stock is moving

As of Sep 18, 2026, SNGX closed down 1.36% at $0.3700. No new same-company headline was identified in the current news window.

Company overview

Rare-Disease Biopharmaceutical Company

Soligenix develops therapies for rare diseases with substantial unmet need. Its pipeline has included oncology, inflammatory-disease and biodefense programs.

HyBryte

HyBryte is a synthetic hypericin photodynamic therapy developed for cutaneous T-cell lymphoma. Its confirmatory Phase 3 FLASH2 study was stopped for futility following an interim analysis, creating uncertainty around the program's path forward.

Dusquetide

SGX945, or dusquetide, is an innate-defense regulator that has generated prior clinical data in Behçet's disease. Soligenix is evaluating strategic options, including whether to advance this program.

Future catalysts

    Recent news

    1. 01

      Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results

    2. 02

      Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine

    3. 03

      Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo

    4. 04

      Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

    5. 05

      Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryteâ„¢ in Treatment of Cutaneous T-Cell Lymphoma

    Similar stocks

    Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

    MBRX

    Moleculin Biotech, Inc.

    UNCY

    Unicycive Therapeutics

    NVIV

    InVivo Therapeutics

    IGC

    IGC Pharma, Inc.

    DRMA

    Dermata Therapeutics

    ASLN

    ASLAN Pharmaceuticals

    TLSA

    Tiziana Life Sciences

    ACST

    Acasti Pharma

    Frequently Asked Questions

    What is the current stock price of SOLIGENIX (SNGX)?

    SOLIGENIX (SNGX) most recently closed at 0.37 USD, a -1.36% move versus the previous session.

    What is the market cap of SOLIGENIX (SNGX)?

    SOLIGENIX currently has a market capitalization of 11.1M USD on BioPharmSignal.

    What does SOLIGENIX do?

    Rare-Disease Biopharmaceutical Company Soligenix develops therapies for rare diseases with substantial unmet need. Its pipeline has included oncology, inflammatory-disease and biodefense programs. HyBryte HyBryte is a synthetic hypericin photodynamic therapy developed for cutaneous T-cell lymphoma. Its confirmatory Phase 3 FLASH2 study was stopped for...

    On which exchange is SNGX stock listed?

    SOLIGENIX (SNGX) is associated with NASDAQ, United States, Biopharma.

    What is Rare-Disease?

    Rare-Disease Biopharmaceutical Company Soligenix develops therapies for rare diseases with substantial unmet need.

    Which conditions is SOLIGENIX targeting with Rare-Disease?

    SOLIGENIX is associated with oncology, rare disease based on its company overview and current catalyst commentary.

    What is Biopharmaceutical?

    Rare-Disease Biopharmaceutical Company Soligenix develops therapies for rare diseases with substantial unmet need.

    What is Soligenix?

    Rare-Disease Biopharmaceutical Company Soligenix develops therapies for rare diseases with substantial unmet need.